급성기 뇌졸중 환자에서 Brain Natriuretic Peptide가 갖는 예후 인자적 가치 = Prognistic Value of Brain Natriuretic Peptide on Patients Acute Phase of Stroke

다국어 초록 (Multilingual Abstract)

Background: Brain Natriuretic Peptide (BNP) Brain natriuretic peptides (BNP) has provided prognostic information in various patient populations especially in heart failure and coronary syndromes. However, the prognostic value of BNP among patients with acute stroke remains unclear, although elevated peptide levels have occasionally been observed. We measured plasma BNP at admission in acute ischemic stroke patients without evident cardiac disease. We compaired the relationship between plasma BNP level and the course of clinical neurological deficits.
Methods : A series of 75 patients (mean age, 64.0 ± 11.0 years) in acute ischemic stroke without evident cardiac disease underwent a comprehensive clinical examination and measurements of plasma BNP at admission in the acute phase of stroke. The relation of laboratory values to risk factors for all-cause mortality, stroke subtype classification, clinical course, and outcome after 30 days were analyzed. Control group was consisted of 31 subjects without neurological focal deficits.
Results : Plasma concentrations of BNP (124.7 ± 209.1 pg/ml) in the stroke patients were significantly higher than those of the healthy subjects (39.1 ± 27.7 pg/ml, P <0.018, respectively). The proportion of patients with bad outcome was increased significantly in the group with high BNP level. Using univariate regression analysis, significant relation of BNP to morbidity and mortality found in acute ischemic stroke patients.
Conclusion : Plasma levels of BNP were elevated in the acute phase of stroke and predict clinical outcome including poststroke mortality.

목차 (Table of Contents)

• 서론
• 연구 대상 및 방법
• 1. 연구대상
• 2. 연구방법
• 3. 통계분석
• 결과
• 1. 뇌경색 환자군의 임상적 특징
• 2. 사망률과 임상경과
• 고찰
• 결론
• 참고문헌

참고문헌 (Reference)

• 1 한림대학교 의료원, "한림대학교 의료원 연보. 1981-2000"
• 2 통계청, "사망원인통계연보"
• 3 Maisel AS, "Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction" 141 (141): 367-374, 2001
• 4 Jesper K. Jensen, "Usefulness of Natriuretic Peptide Testing for Long-Term Risk Assessment Following Acute Ischemic Stroke" 104 (104): 287-291, 2009
• 5 Sviri GE, "Role of brain natriuretic peptide in cerebral vasospasm" 145 (145): 851-860, 2003
• 6 Yoshikawa TT, "Role of anaerobic bacteria in subdural empyema. Report of four cases and review of 327 cases from the English literature" 58 : 99-104, 1975
• 7 Maisel A, "Rapid Emergency Department Heart Failure Outpatient Trial investigators: Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath" 44 (44): 1328-1333, 2004
• 8 Herring N, "Natriuretic peptides like NO facilitate cardiac vagal neurotransmission and bradycardia via a cGMP pathway" 281 (281): H2318-H2327, 2001
• 9 Mäkikallio AM, "Natriuretic peptides and mortality after stroke" 36 (36): 1016-1020, 2005
• 10 Levin ER, "Natriuretic peptides" 339 (339): 321-328, 1998
• 11 Jernberg T, "N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation" 40 (40): 437-445, 2002
• 12 Giuffrida R, "Ischemia-induced changes in the immunoreactivity for endothelin and other vasoactive peptides in the brain of the Mongolian gerbil" 20 (20): S41-S44, 1992
• 13 Peduzzi P, "Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates" 48 (48): 1503-1510, 1995
• 14 Nogami M, "Immunohistochemistry of atrial natriuretic peptide in brain infarction" 33 (33): 87-90, 2001
• 15 Takahashi K, "Human brain natriuretic peptide-like immunoreactivity in human brain" 13 (13): 121-123, 1992
• 16 Mäkikallio AM, "Heart rate dynamics predict poststroke mortality" 62 (62): 1822-1826, 2004
• 17 Morrow DA, "Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST -elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18" 41 (41): 1264-1272, 2003
• 18 Adams HP Jr, "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment" 24 (24): 35-41, 1993
• 19 Eguchi K, "Circadian variation of blood pressure and neurohumoral factors during the acute phase of stroke" 24 (24): 109-114, 2002
• 20 Etgen T, "Cardiac troponins and N-terminal pro-brain natriuretic peptide in acute ischemic stroke do not relate to clinical prognosis" 36 (36): 270-275, 2005
• 21 Ruskoaho H, "Cardiac hormones as diagnostic tools in heart failure" 24 (24): 341-356, 2003
• 22 Wallén T, "Brain natriuretic peptide predicts mortality in the elderly" 77 (77): 264-267, 1997
• 23 Mukoyama M, "Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide" 87 (87): 1402-1412, 1991
• 24 Richards AM, "B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction" 107 (107): 2786-2792, 2003
• 25 Donald WR, "B-type natriuretic peptide in cardiovascular disease" 362 (362): 316-322, 2003
• 26 McCullough PA, "B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study" 106 (106): 416-422, 2002
• 27 Sudoh T, "A new natriuretic peptide in porcine brain" 332 (332): 78-81, 1988